INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
SKIN
SUSTAINABILITY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
MEDIA PACK
CONTRIBUTE
Subscribe
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
SKIN
SUSTAINABILITY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
MEDIA PACK
CONTRIBUTE
SEARCH
SEARCH
advanced search
EXPERT VIEW
EXPERT VIEW
Greg Anderson
CHALLENGES & OPPORTUNITIES TO OPTIMISE SUSTAINABILITY IN PHARMACEUTICAL PACKAGING & COMBINATION DEVICES
Greg Anderson discusses the need to improve the sustainability and circularity of pharmaceutical packaging and drug delivery devices, looking at the challenges and providing a clear outline of the potential opportunities for improvement.
EXPERT VIEW
Markus Laubscher
ENABLING A SUSTAINABLE FUTURE FOR pMDIs WITH LOW-GWP MEDICAL PROPELLANTS
Markus Laubscher discusses the role of pressurised metered dose inhalers in the context of healthcare’s drive towards sustainability, considering the need for lower-global-warming-potential propellants and why it is important to preserve these inhalers as a key aspect of respiratory care.
EXPERT VIEW
Dr Matthew Owen
INTRANASAL DRUG DELIVERY: FORMULATION, DEVICE DESIGN & CHARACTERISATION STRATEGIES
Dr Matthew Owen reviews the formulation and device challenges, designs and considerations that are shaping the nasal delivery market.
EXPERT VIEW
Gregg Draudt
INTRAVITREAL INJECTIONS – WHAT IS CAUSING PATIENTS TO DISCONTINUE THERAPY AND WHY IS IT SO HARD TO FIX?
Gregg Draudt considers the significant issue of treatment discontinuation in intravitreal therapies, digging into the root causes of poor adherence and what will be required to reverse this trend in a way that caters to the full range of stakeholders, who often have contradictory requirements.
EXPERT VIEW
Tina Rogers
WuXi AppTec
ADDRESSING OCULAR SAFETY CHALLENGES IN ADC DEVELOPMENT
Dr Tina Rogers discusses antibody-drug conjugates and their potential in direct targeting and treatment of cancers, going further to assess the risks of these treatments and how they can be mitigated.
EXPERT VIEW
Tom Oakley
TRENDS FOR 2026
A new reality is forming as we enter 2026 – it will not be “business as usual”. Geopolitical forces in the largest market for pharmaceuticals, the US, are likely to mean substantial changes. Here, Tom Oakley and Alex Vasiev cover those changes, the incretin juggernaut and the march of technical progress with “minitablet” dispensers, large-volume injectors and dual-chamber devices.
EXPERT VIEW
Dr Oliver Eden
DEVELOPMENTAL ADVANTAGES IN INJECTABLE COMBINATION DRUG PRODUCTS
Oliver Eden and Travis Webb consider how regulatory considerations and patient-centric device designs are transforming the landscape of self-administered injectable drugs.
EXPERT VIEW
Angela Shotton
DESIGNING SUSTAINABLE DRUG DELIVERY DEVICE PACKAGING: TRENDS, CHALLENGES AND REGULATORY IMPLICATIONS
Angela Shotton and Nic Hunt, look at the evolving landscape of the pharmaceutical packaging landscape and consider how the industry is meeting sustainability and regulatory requirements.
EXPERT VIEW
Paul Jansen
FRACTIONAL INVESTMENT IN DEVICE PLATFORMS – A NEW FUNDING PARADIGM
Drawing on his extensive experience in the drug delivery device industry, Paul Jansen considers how funding for delivery device development has shifted over the years, from the pre-platform model to currently accepted practice and looks forward to how it may further evolve to support the development of novel devices in the biologics space and beyond.
EXPERT VIEW
Tim Quigg
THE PLATFORM PARADOX: DEVICE DEVELOPMENT CHALLENGES WITHIN FAST EVOLVING DRUG DISCOVERY PIPELINES
Tim Quigg, Mariam Al-Amari and Joel Gresham discuss how to enable high-dose delivery for novel biologics, using
ex vivo
and
in silico
approaches to accelerate drug-device development and improve device performance, thus de-risking projects and saving costs.
EXPERT VIEW
Dr Fiona McLaughlin
IMPROVING RNA THERAPEUTIC TARGETING BEYOND DELIVERY
Dr Fiona McLaughlin and Dr Mark Edbrooke discuss the possibilities for developing novel cancer treatments using functionalised nanoparticles, in order to transport a variety of therapies into the tumour microenvironment.
EXPERT VIEW
Dr Max Chambers
REVEALING THE FRONTIER: DRUG DELIVERY CHALLENGES AND INNOVATIONS IN OCULAR GENE THERAPY
Dr Max Chambers discusses novel approaches for delivering ocular gene therapies, summarising the challenges and benefits of various delivery routes and exploring the devices used to successfully improve vision.
EXPERT VIEW
Bharat Arora
DRUG DELIVERY IN CELL AND GENE THERAPY: WHY EARLY DEVICE DEVELOPMENT MATTERS
Bharat Arora discusses how the delivery method for a cell and gene therapy is an integral part of the overall product, inextricable from the therapy itself, and how properly synchronising drug and delivery device development can greatly benefit the overall development programme.
EXPERT VIEW
Dr Akshay Peer
CELL AND GENE THERAPY DIGITAL INFRASTRUCTURE: REPLACING FRAGMENTATION WITH STANDARDISATION
Dr Akshay Peer examines why bespoke digital systems for cell and gene therapies are reaching a saturation point, how clinicians experience this fragmentation on the ground and why a shift towards standardisation is becoming essential for enabling safe, scalable and sustainable delivery of these innovative treatments.
EXPERT VIEW
Dr Elodie Bovier
MAPPING INNOVATION IN mRNA DELIVERY THROUGH PATENT TRENDS
Dr Elodie Bovier considers the evolution of messenger RNA therapeutics in biotechnology, examining patent trends and exploring how they have triggered litigation in the field, demonstrating the growth and maturity of this sector.
EXPERT VIEW
Dr Ethan Miller
SHEAR RELIEF: MINIMISING SHEAR STRESS IN CGT PRODUCTION
Dr Ethan Miller examines the manufacturing of cell and gene therapies where shear stress can impact cells and explores strategies to mitigate such damage, helping to ensure that therapies retain their viability, functionality and therapeutic potency from production through to administration.
EXPERT VIEW
Jessica Alzamora
PRECISION DELIVERY: THE MISSING LINK IN CELL & GENE THERAPY
Jessica Alzamora, Dr Karla Sanchez and Emily Chang discuss the necessity for precision when delivering cell and gene therapies, explore how this precision can be designed and demonstrated, then go on to describe how a minimum viable product approach to device development can act as a strong predictor of a successful delivery device.
EXPERT VIEW
Alejandra Sanchez
DRUG DELIVERY DEVICE INNOVATION IN CELL AND GENE THERAPIES
Dr Alejandra Sanchez and Charlie Dean consider the evolution of drug delivery technologies and how cell and gene therapies are showing promise as a new class of medicine to correct disease at its source.
EXPERT VIEW
Mark Parry
RESPIRATORY MUCOSAL VACCINATION: HOW COULD WE DELIVER ANOTHER GLOBAL VACCINATION RESPONSE WITH CURRENT DEVICE TECHNOLOGIES?
Mark Parry discusses the potential needs and opportunities for respiratory drug delivery devices in the context of a hypothetical global vaccination strategy, considering a variety of factors and how different respiratory device approaches could perform.
EXPERT VIEW
Dr Yannick Baschung
STRESS-TESTING INHALED MEDICINE SO PATIENTS CAN BREATHE EASIER
Dr Yannick Baschung discusses the benefits and challenges of orally inhaled and nasal drug products and examines how drug developers can stress test their products to improve regulatory success and patient safety, as well as how partnering with an expert CRO can provide an efficient way of performing critical characterisation testing.
EXPERT VIEW
Jamie Clayton
DISSOLUTION TESTING FOR ORALLY INHALED PRODUCTS: CONFRONTING THE CHALLENGES, REALISING THE POTENTIAL
As dissolution testing rises up the agenda for orally inhaled product developers, Jamie Clayton explores drivers behind its adoption and key considerations for developing a robust and relevant method.
EXPERT VIEW
Dr Peter Harley
HOW CUTTING EDGE IN SILICO APPROACHES CAN REDUCE TIME AND RISK IN DEVELOPMENT OF INHALATION DEVICES
Dr Peter Harley, Mariam Al-Amari and Matt Jones explore how in silico approaches can transform pulmonary and nasal drug delivery device development, illustrating through case studies – spanning low-global-warming potential propellants, assembly robustness, device-user interaction, variability and capsule piercing dynamics – how simulation-led in silico approaches can improve understanding of device performance and identify risks early, reducing development costs and accelerating the path to more reliable, innovative and patient-friendly drug-device systems.
EXPERT VIEW
Chris Gilmor
DELIVERING AND MAINTAINING OPTIMAL DPI PERFORMANCE
Chris Gilmor considers the issues affecting dry powder inhalers and explains how formulators use a range of techniques to ensure dose dispersion and API detachment. He goes on to explain the importance of controlling the moisture level in these devices and how it can affect the drug delivery performance of the formulation.
EXPERT VIEW
Maria Riccius
SUSTAINABLE DRUG DELIVERY SYSTEMS: COLLABORATIVE INNOVATION TO SHRINK PHARMA’S PACKAGING FOOTPRINT
Maria Riccius and Dr Uwe Hanenberg explore how CDMOs are playing a pivotal role in driving drug delivery’s transformation towards sustainability, examining the most promising advances and highlighting why collaborative innovation is essential to achieving measurable environmental gains, both within organisations and across the pharmaceutical value chain.
Prev
1
2
3
4
…
15
Next
Top
